Current update on stroke ischemic management

Andhika Tomy Permana, Nur Setiawan Suroto, M. Parenrengi, A. Bajamal, Pudji Lestari, A. Fauzi
{"title":"Current update on stroke ischemic management","authors":"Andhika Tomy Permana, Nur Setiawan Suroto, M. Parenrengi, A. Bajamal, Pudji Lestari, A. Fauzi","doi":"10.21744/ijhms.v5n1.1851","DOIUrl":null,"url":null,"abstract":"Stroke is one of the most important causes of morbidity and mortality worldwide, with survivors subjected to long-term disability. Stroke is classified as ischemic and hemorrhagic. 87 % of strokes are classified as ischemic. Except for thrombolytic therapy, there is no established treatment to reduce the neurological deficits caused by an ischemic stroke. Therefore, it is necessary to develop new therapeutic strategies designed to improve neurological functions after ischemic stroke. Stem cell-based therapies aim to promote neurogenesis and replacement of lost neurons or protect surviving neurons to improve neurological recovery. Further understanding of the mechanisms by which the stem cells exert their beneficial effect could potentially revolutionize the field. The next decade of stem cell research in stroke needs to focus on. Although still in need of exploration, stem cell treatments for stroke may offer ways to protect and replace neurons to improve outcomes for stroke patients.","PeriodicalId":51699,"journal":{"name":"International Journal of Medical Research & Health Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical Research & Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21744/ijhms.v5n1.1851","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16

Abstract

Stroke is one of the most important causes of morbidity and mortality worldwide, with survivors subjected to long-term disability. Stroke is classified as ischemic and hemorrhagic. 87 % of strokes are classified as ischemic. Except for thrombolytic therapy, there is no established treatment to reduce the neurological deficits caused by an ischemic stroke. Therefore, it is necessary to develop new therapeutic strategies designed to improve neurological functions after ischemic stroke. Stem cell-based therapies aim to promote neurogenesis and replacement of lost neurons or protect surviving neurons to improve neurological recovery. Further understanding of the mechanisms by which the stem cells exert their beneficial effect could potentially revolutionize the field. The next decade of stem cell research in stroke needs to focus on. Although still in need of exploration, stem cell treatments for stroke may offer ways to protect and replace neurons to improve outcomes for stroke patients.
脑卒中缺血性管理的最新进展
中风是世界范围内发病率和死亡率的最重要原因之一,幸存者遭受长期残疾。中风分为缺血性和出血性。87%的中风被归类为缺血性中风。除了溶栓治疗外,目前还没有确定的治疗方法来减少缺血性中风引起的神经功能障碍。因此,有必要开发新的治疗策略来改善缺血性脑卒中后的神经功能。基于干细胞的治疗旨在促进神经发生和替代丢失的神经元或保护存活的神经元,以改善神经系统的恢复。进一步了解干细胞发挥其有益作用的机制可能会彻底改变这一领域。下一个十年中风干细胞研究需要关注。尽管仍需探索,干细胞治疗中风可能提供保护和替代神经元的方法,以改善中风患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信